甲强龙治疗慢性阻塞性肺疾病急性加重期疗效观察

Therapeutic effect of Jiaqianglong on acute exacerbation of chronic obstructive pulmonary disease

目的探析慢性阻塞性肺疾病(Chronic Obstructive Pulmonary Disease,COPD)急性加重期患者应用甲强龙治疗的临床效果。方法选择本院2016年1月～2017年12月来治疗的90例COPD急性加重期患者为观察对象,依照随机数字表法分为两组,即对照组(n=45)、试验组(n=45)。对照组患者应用常规治疗,试验组患者在对照组基础上加用甲强龙静脉滴注治疗,对两组患者临床疗效、临床症状及体征缓解时间及肺功能指标水平进行统计比较。结果试验组临床总有效率为91.11%,与对照组的73.33%比较,差异有统计学意义(P<0.05)。试验组喘息缓解时间、咳嗽消失时间、肺部湿啰音消失时间、肺部干鸣音消失时间明显短于对照组,差异有统计学意义(P<0.05)。试验组治疗后1 s用力呼气容积(FEV_1)、FEV_1/用力肺活量(FVC)明显大于对照组,差异有统计学意义(P<0.05)。结论 COPD急性加重期患者应用甲强龙治疗的临床效果十分显著,不仅可以减轻患者临床症状及体征,还可以改善患者肺功能指标,值得在临床治疗中应用与推广。

Objective To investigate the clinical effect of treatment with methylprednisolone in patients with acute exacerbation of chronic obstructivepulmonary disease （COPD）. Methods Ninety patients with acute exacerbation of COPD who were treated in our hospital from January2016 to December 2017 were enrolled in the study. They were divided into two groups according to the random number table, namely the controlgroup （n=45） and the experimental group （n=45）. The patients in the control group were treated with conventional therapy. The patients in the experimentalgroup were treated with intravenous infusion of methylprednisolone on the basis of the control group. The clinical efficacy, clinical symptomsand signs of remission and the level of pulmonary function were statistically compared between the two groups. Results The total effective rate of the experimental group was 91.11%, which was statistically significant compared with 73.33% of the control group （P〈0.05）. The time of wheezingremission, the time of cough disappearance, the disappearance time of lung wetness, and the disappearance time of lung dryness were significantlyshorter in the experimental group than in the control group （P〈0.05）. The forced expiratory volume （FEV1） and FEV1/forced vital capacity（FVC） at 1s after treatment were significantly higher than those in the control group, and the difference was statistically significant （P〈0.05）.Conclusion The clinical effect of treatment with methylprednisolone in patients with acute exacerbation of COPD is very significant. It can not onlyreduce the clinical symptoms and signs of patients, but also improve the lung function index of patients. It is worthy of application and promotion inclinical treatment.